 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LGM2605 / LignaMed
Journal: Synthetic Secoisolariciresinol Diglucoside (LGM2605) Prevents Asbestos-Induced Inflammation and Genotoxic Cell Damage in Human Mesothelial Cells. (Pubmed Central) - Sep 18, 2022
Levels of MDA and 8-iso-PGF2α, markers of oxidative cell injury, were significantly (p < 0.001) reduced by 80.5% ± 0.1% and 76.6% ± 0.3%, respectively. LGM2605, given preventively, reduced ROS generation, DNA damage, and inflammasome-activated cytokine release and key inflammatory mediators implicated in asbestos-induced malignant transformation of normal mesothelial cells.
- | LGM2605 / LignaMed
Preclinical, Journal: Late Inflammation Induced by Asbestiform Fibers in Mice Is Ameliorated by a Small Molecule Synthetic Lignan. (Pubmed Central) - Dec 29, 2021
LGM2605 countered these changes similarly among male and female mice, ameliorating late inflammation and altering immune responses in late post-LA exposure. These data support possible efficacy of LGM2605 in the prolonged treatment of LA-associated disease and other inflammatory conditions.
- | LGM2605 / LignaMed
Preclinical, Journal: Short-term exposure to synthetic flaxseed lignan LGM2605 alters gut microbiota in mice. (Pubmed Central) - Nov 24, 2021
The study here identifies for the first time significant alterations in the gut microbiota of mice following oral administration of LGM2605, in general shifting toward a more anti-inflammatory composition. These findings lay the foundation for future investigations utilizing LGM2605 to control gut dysbiosis and, by extension, systemic inflammation.
- | LGM2605 / LignaMed
Preclinical, Journal: Copper Oxide Nanoparticle-Induced Acute Inflammatory Response and Injury in Murine Lung Is Ameliorated by Synthetic Secoisolariciresinol Diglucoside (LGM2605). (Pubmed Central) - Nov 4, 2021
CuO-NPs induced a significant inflammatory influx, inflammasome-relevant cytokine release, and chlorination damage in mouse lungs, which was mitigated by the action of LGM2605. Preventive action of LGM2605 ameliorated the adverse effects of CuO-NP in lung.
- | LGM2605 / LignaMed
Journal: Assessment of a Small Molecule Synthetic Lignan in Enhancing Oxidative Balance and Decreasing Lipid Accumulation in Human Retinal Pigment Epithelia. (Pubmed Central) - Jun 30, 2021
The addition of LGM2605 resulted in enhanced mitochondrial capacity, decreased lipid accumulation and amelioration of IL-1 β release in a model of defective lipid homeostasis. Collectively, these studies suggest that lipid overload decreases mitochondrial function and increases the inflammatory response, with LGM2605 acting as a protective agent.
- | LGM2605 / LignaMed
Journal: Radiation activates myeloperoxidase (MPO) to generate active chlorine species (ACS) via a dephosphorylation mechanism - inhibitory effect of LGM2605. (Pubmed Central) - Mar 9, 2021
We demonstrate that γ-radiation induces MPO-dependent generation of ACS, which is dependent, at least in part, by protein tyrosine and Ser/Thr dephosphorylation and is reduced by LGM2605. This study identified for the first time a novel protein dephosphorylation-dependent mechanism of radiation-induced MPO activation.
- | LGM2605 / LignaMed
Journal: Ozone-induced enhancement of airway hyperreactivity in rhesus macaques: Effects of antioxidant treatment. (Pubmed Central) - Jul 29, 2020
ILC2s, CD1c myeloid dendritic cells, and CD4 T cells are selectively involved in O-induced asthma exacerbation. The inflammatory changes were partially prevented by antioxidant pretreatment with LGM2605, which had an unexpectedly disproportionate protective effect on AHR.
- | LGM2605 / LignaMed
Preclinical, Journal: Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits Libby amphibole fiber-induced acute inflammation in mice. (Pubmed Central) - May 17, 2020
Following acute exposure to Libby Amphibole (LA) asbestos-like fibers, synthetic secoisolariciresinol diglucoside (LGM2605), a small synthetic molecule, significantly reduced the LA-induced increase in spleen weight and peritoneal inflammation in C57BL/6 male and female mice. Our findings highlight that LGM2605 has immunomodulatory properties and may, thus, likely be a chemopreventive agent for LA-induced diseases.
- LGM2605 / LignaMed
Antioxidant Gene Expression in Airway Smooth Muscle and Epithelial Cells is Upregulated by Synthetic Secoisolaricesinol Diglucoside (LGM2605) (Convention Center, 200 Level, Hall D) - Mar 1, 2020 - Abstract #AAAAI2020AAAAI_1452;
Our findings highlight that LGM2605 has immunomodulatory properties and may, thus, likely be a chemopreventive agent for LA-induced diseases. Our data suggest that airway smooth muscle is highly sensitive to oxidative stress as well as to the anti-oxidant effects of LGM2605 raising the potential of a novel treatment approach in asthma.
- | LGM2605 / LignaMed
Journal: Chemically synthesized Secoisolariciresinol diglucoside (LGM2605) improves mitochondrial function in cardiac myocytes and alleviates septic cardiomyopathy. (Pubmed Central) - Jan 10, 2020
In addition to protecting against cardiac dysfunction, daily treatment with LGM2605 and antibiotic ertapenem (70 mg/kg) protected against CLP-associated mortality and reversed hypothermia when compared against mice receiving ertapenem and saline. Therefore, treatment of septic mice with LGM2605 emerges as a novel pharmacological approach that reduces cardiac ROS accumulation, protects cardiac mitochondrial function, alleviates cardiac dysfunction, and improves survival.
- LGM2605 / LignaMed
FOXO1 Increases CardiοMyocyte KLF5 Expression, Which Induces Oxidative Stress, Lipotoxicity and Cardiomyopathy in Type 1 Diabetes (120B) - Aug 21, 2019 - Abstract #AHA2019AHA_5389;
Antioxidant treatment (LGM2605) of αMHC-rtTA- Klf5 mice and diabetic C57BL/6 mice, improved cardiac dysfunction partially...In conclusion, we show that FOXO1 can induce KLF5 in cardiomyocytes, which drives DbCM in a PPARα-independent manner. Thus, KLF5 inhibition holds promise as a therapeutic intervention for DbCM.